Thymosin Alpha-1
Thymosin Alpha-1 (Thymalfasin)
The thymus gland's master immune modulator
How it works
Thymosin Alpha-1 activates innate immunity by triggering Toll-like receptor (TLR) signaling, maturation of dendritic cells, and differentiation of Th1 helper T-cells. It upregulates MHC class I expression on tumor cells, improving immune recognition.
What the research explores
In published research, Thymosin Alpha-1 has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.
- Enhances T-cell maturation and immune competence
- Improves response to viral infections (HIV, HBV, HCV)
- Approved in 37+ countries for HBV and HCV
- Reduces immunosuppression in cancer patients undergoing chemotherapy
- Potent adjuvant when combined with vaccines
- Anti-tumor properties via immune sensitization
Thymosin Alpha-1 (Zadaxin) is approved in over 37 countries for hepatitis B, hepatitis C, and as a vaccine adjuvant, making it the most clinically validated immune-modulating peptide.
Adverse events & gaps
Excellent safety profile across decades of clinical use. Mild administration-site reactions only.
Stay Informed on
Peptide Research
Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.
No spam. Unsubscribe at any time.